Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 0.82 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.82 |
| ▸ | MMP3 | P08254 | 2/20 | 0.72 |
| ▸ | MMP13 | P45452 | 2/20 | 0.72 |
| ▸ | MYC | P01106 | 3/20 | 0.68 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.68 |
| ▸ | MAX | P61244 | 2/20 | 0.68 |
| ▸ | IL1RN | P18510 | 1/20 | 0.67 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.67 |
| ▸ | PIM1 | P11309 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.63 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247509 | 1.00 | NAT1 (1.00) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL1247510 | 1.00 | NAT1 (1.00) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL1812224 | 0.90 | NAT1 (1.00) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL3491175 | 0.90 | NAT1 (1.00) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL4416451 | 0.90 | NAT1 (1.00) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL12891790 | 0.87 | PIM1 (0.83) | NAT1CA2CISD1PIM1RAB9A | |
| SCHEMBL1248782 | 0.87 | PIM1 (0.83) | NAT1CA2CISD1PIM1RAB9A | |
| SCHEMBL1248780 | 0.87 | PIM1 (0.83) | NAT1CA2CISD1PIM1RAB9A | |
| SCHEMBL19991267 | 0.87 | NAT1 (0.76) | NAT1CA2EPHX1MMP3MMP13 | |
| SCHEMBL18102890 | 0.87 | NAT1 (0.76) | NAT1CA2EPHX1MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090204336-A1 | PDZ-Domain Modulators | FORSCHUNGSVERBUND BERLIN E. V. (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| EP-0212617-B1 | PROCESS FOR PRODUCING 4-BIPHENYLYLACETIC ACID | LEDERLE (JAPAN) LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| EP-0212617-A1 | Process for producing 4-biphenylylacetic acid | LEDERLE (JAPAN) LTD. (JP) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | NAT1 867/4885CA2 4417/4885EPHX1 3076/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | NAT1 867/4885CA2 4417/4885EPHX1 3076/4885 |
| US-20090204336-A1 | PDZ-Domain Modulators | PDLIM5, DVL1, PSD | NAT1 4324/4885CA2 4307/4885EPHX1 2302/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NAT1 4542/4885CA2 4342/4885EPHX1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.